Epsilogen Ltd

R&D/Manufacturing

  • Funding stage: Series B
  • Technology type: Platform Technology
  • West London
Phone
+442036577612
Membership category
Corporate

ARC West London, Manbre Road, Hammersmith, London, W6 9RH, United Kingdom

Epsilogen Ltd at a glance

Epsilogen is the world’s leading pan-isotype antibody therapeutic company for the treatment of cancer.

About Epsilogen Ltd

Epsilogen's unique and proprietary expertise is focused on the discovery and development of immunoglobulin IgE, IgA and IgG-based therapeutics, by matching the attributes of each isotype to a given cancer or by combining different isotypes into single antibody molecules – potentially enhancing potency and performance.

Our lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic. Found to be safe and well tolerated in a Phase I study with early signs of clinical activity, it has now moved into a Phase Ib study in platinum-resistant ovarian cancer patients.

Therapeutic area(s)